Dr. Ashwin K. Ravichandran, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 567
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Minnesota Medical School
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
IN license 01072393A -
Cardiovascular Disease Physician
IN license 01072393A -
Internal Medicine Physician
IN license 01072393A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Ascension St Vincent Hospital Indianapolis, IN
- Ascension St Vincent Kokomo Kokomo, IN
- Union Hospital Clinton Clinton, IN
- St Vincent Heart Center Carmel, IN
- Saint Joseph Regional Medical Center - Plymouth Plymouth, IN
Medical groups
- St Vincent Medical Group Inc (736 clinicians)
- St Vincent Physician Services Hospital and Health Care Center (275 clinicians)
- Rush Memorial Hospital (69 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 567
- Services billed
- 1,369
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 177 | 129 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 141 | 54 |
| Evaluation of lower heart chamber assist device | 137 | 36 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 127 | 127 |
| Critical care, first 30-74 minutes | 111 | 32 |
| Established patient office or other outpatient visit, 30-39 minutes | 111 | 95 |
| Remote monitoring of pulmonary artery pressure sensor, up to 30 days | 83 | 15 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 61 | 53 |
| Ultrasonic guidance for blood vessel access | 58 | 49 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 50 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Indianapolis, IN | 510 |
| Opsumit (macitentan) | 465 |
| Jardiance (empagliflozin) Other prescribers in Indianapolis, IN | 340 |
| Entresto (sacubitril/valsartan) Other prescribers in Indianapolis, IN | 321 |
| Tyvaso Dpi (treprostinil) | 245 |
| Furosemide Other prescribers in Indianapolis, IN | 214 |
| Metoprolol Succinate Other prescribers in Indianapolis, IN | 195 |
| Tadalafil | 190 |
| Atorvastatin Calcium Other prescribers in Indianapolis, IN | 180 |
| Torsemide Other prescribers in Indianapolis, IN | 177 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 65 payments worth $39,743 in total to this clinician.
| Merck Sharp & Dohme LLC | $13,293 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $12,790 |
| Cvrx, Inc. | $11,041 |
| Abbott Laboratories | $2,249 |
| E.r. Squibb & Sons, L.l.c. | $124 |
| United Therapeutics Corporation | $110 |
| Briohealth Solutions, Inc. | $84.54 |
| Endotronix, Inc. | $32.87 |
| Compensation for services other than consulting (speaking, faculty) | $22,420 |
|---|---|
| Consulting Fee | $7,763 |
| Travel and Lodging | $6,002 |
| Food and Beverage | $3,559 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Cvrx, Inc. Jun 6, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $4,500 |
| Actelion Pharmaceuticals US, Inc. Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,815 |
| Actelion Pharmaceuticals US, Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Cvrx, Inc. Mar 18, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $3,263 |
| Merck Sharp & Dohme LLC Jul 8, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Munster, IN · in-kind | $1,250 |
| Actelion Pharmaceuticals US, Inc. May 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,090 |
| Actelion Pharmaceuticals US, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,090 |
| Actelion Pharmaceuticals US, Inc. Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,090 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Cvrx, Inc. Dec 3, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to Orlando, FL | $655 |
| Cvrx, Inc. Dec 3, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to Orlando, FL | $34.00 |
| Merck Sharp & Dohme LLC Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC Oct 15, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Terre Haute, IN | $150 |
| Actelion Pharmaceuticals US, Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Actelion Pharmaceuticals US, Inc. Oct 14, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Cincinnati, OH · in-kind | $850 |
| Abbott Laboratories Sep 26, 2025 | Travel and Lodging THORATEC HEARTMATE 3 LVAS IMPLANT KIT · Structural Heart · travel to Hershey, PA · in-kind | $332 |
| Actelion Pharmaceuticals US, Inc. Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,090 |
| Actelion Pharmaceuticals US, Inc. Aug 21, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Cincinnati, OH · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,090 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Munster, IN | $150 |
| Merck Sharp & Dohme LLC Jul 8, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Munster, IN · in-kind | $1,250 |
| Cvrx, Inc. Jun 6, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $4,500 |
| Cvrx, Inc. Jun 6, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to Dallas, TX | $92.32 |
| Actelion Pharmaceuticals US, Inc. May 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,090 |
| Cvrx, Inc. May 9, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to Dallas, TX | $430 |
| Cvrx, Inc. Apr 22, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to Tulsa, OK | $797 |
| Cvrx, Inc. Apr 22, 2025 | Travel and Lodging Barostim Neo System · Heart Failure and Hypertension · travel to Arlington, VA | $34.00 |
| Actelion Pharmaceuticals US, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $545 |
| Actelion Pharmaceuticals US, Inc. Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,815 |
| Actelion Pharmaceuticals US, Inc. Mar 26, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Fort Wayne, IN · in-kind | $758 |
| Cvrx, Inc. Mar 18, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $3,263 |
| Abbott Laboratories Jan 31, 2025 | Travel and Lodging THORATEC HEARTMATE 3 LVAS IMPLANT KIT · Structural Heart · travel to Milwaukee, WI · in-kind | $145 |
| Abbott Laboratories Jan 9, 2025 | Travel and Lodging THORATEC HEARTMATE 3 LVAS IMPLANT KIT · Structural Heart · travel to Wauwatosa, WI · in-kind | $156 |
| Abbott Laboratories Jan 9, 2025 | Travel and Lodging THORATEC HEARTMATE 3 LVAS IMPLANT KIT · Structural Heart · travel to Milwaukee, WI · in-kind | $148 |
| Abbott Laboratories Jan 9, 2025 | Travel and Lodging THORATEC HEARTMATE 3 LVAS IMPLANT KIT · Structural Heart · travel to Wauwatosa, WI · in-kind | $9.02 |
| Actelion Pharmaceuticals US, Inc. Jan 2, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Fort Wayne, IN · in-kind | $5.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 8 companies. The companies reported $461,589 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - PROACTIVE-HF2
Endotronix, Inc. - Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF)
E.r. Squibb & Sons, L.l.c. - Innovate
Briohealth Solutions, Inc. - NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Laboratories - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Ma…
Janssen Research & Development, LLC - PROACTIVE-HF
Endotronix, Inc. - PSR-MCS
Medtronic, Inc. - Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06122779
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.